v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Common Shares
Additional Paid in Capital
Accumulated Deficit
Noncontrolling Interest
Total
Beginning Balance at Sep. 30, 2023 $ 1 $ 307,398,305 $ (302,447,147) $ (78,747) $ 4,872,412
Beginning Balance (in shares) at Sep. 30, 2023 911        
Increase (Decrease) in Stockholders' Equity          
Stock based compensation expense   572,293     572,293
Deemed dividend - warrant repricing   233,087 (233,087)    
Adjustment for reverse split (in shares) 113        
Net loss     (6,992,521) (95,785) (7,088,306)
Ending Balance at Sep. 30, 2024 $ 14 318,815,358 (309,672,755) (174,532) $ 8,968,085
Ending Balance (in shares) at Sep. 30, 2024 13,755       13,755
Increase (Decrease) in Stockholders' Equity          
Exercise of warrants $ 3 508,597     $ 508,600
Exercise of warrants (in shares) 3,422        
Exercise of warrants, cashlessly $ 28 (28)      
Exercise of warrants, cashlessly (in shares) 27,895        
Stock based compensation expense   28,973     28,973
Common stock and pre-funded warrants issued in registered direct offering, net of offering costs $ 27 5,712,673     5,712,700
Common stock and pre-funded warrants issued in registered direct offering, net of offering costs (in shares) 27,083        
Deemed dividend - warrant repricing   14,907,223 (14,907,223)    
Net loss     (2,639,412) (29,301) (2,668,713)
Ending Balance at Dec. 31, 2024 $ 72 339,972,796 (327,219,390) (203,833) 12,549,645
Ending Balance (in shares) at Dec. 31, 2024 72,155        
Beginning Balance at Sep. 30, 2024 $ 14 318,815,358 (309,672,755) (174,532) $ 8,968,085
Beginning Balance (in shares) at Sep. 30, 2024 13,755       13,755
Increase (Decrease) in Stockholders' Equity          
Net loss         $ (6,004,833)
Ending Balance at Mar. 31, 2025 $ 422 364,902,558 (354,442,994) (235,778) 10,224,208
Ending Balance (in shares) at Mar. 31, 2025 422,095        
Beginning Balance at Sep. 30, 2024 $ 14 318,815,358 (309,672,755) (174,532) $ 8,968,085
Beginning Balance (in shares) at Sep. 30, 2024 13,755       13,755
Increase (Decrease) in Stockholders' Equity          
Exercise of warrants, cashlessly $ 1,314 (1,314)      
Exercise of warrants, cashlessly (in shares) 1,314,112        
Stock based compensation expense   (102,021)     $ (102,021)
Deemed dividend - warrant repricing   54,326,896 (54,326,896)    
Adjustment for reverse split $ 79 (79)      
Adjustment for reverse split (in shares) 78,704        
Net loss     (15,160,724) (188,522) (15,349,246)
Ending Balance at Sep. 30, 2025 $ 1,663 381,463,459 (379,160,375) (363,054) $ 1,941,693
Ending Balance (in shares) at Sep. 30, 2025 1,662,601       1,662,601
Beginning Balance at Dec. 31, 2024 $ 72 339,972,796 (327,219,390) (203,833) $ 12,549,645
Beginning Balance (in shares) at Dec. 31, 2024 72,155        
Increase (Decrease) in Stockholders' Equity          
Exercise of warrants $ 30 984,142     984,172
Exercise of warrants (in shares) 30,003        
Exercise of warrants, cashlessly $ 315 (315)      
Exercise of warrants, cashlessly (in shares) 314,845        
Stock based compensation expense   26,511     26,511
Deemed dividend - warrant repricing   23,919,429 (23,919,429)    
Adjustment for reverse split $ 5 (5)      
Adjustment for reverse split (in shares) 5,092        
Net loss     (3,304,175) (31,945) (3,336,120)
Ending Balance at Mar. 31, 2025 $ 422 364,902,558 (354,442,994) (235,778) 10,224,208
Ending Balance (in shares) at Mar. 31, 2025 422,095        
Beginning Balance at Sep. 30, 2025 $ 1,663 381,463,459 (379,160,375) (363,054) $ 1,941,693
Beginning Balance (in shares) at Sep. 30, 2025 1,662,601       1,662,601
Increase (Decrease) in Stockholders' Equity          
Exercise of warrants $ 143 731,621     $ 731,764
Exercise of warrants (in shares) 142,608        
Exercise of warrants, cashlessly $ 407 (407)      
Exercise of warrants, cashlessly (in shares) 406,730        
Stock based compensation expense   633,120     633,120
Common stock and pre-funded warrants issued in PIPE, net of offering cost $ 2,550 24,900,300     24,902,850
Common stock and pre-funded warrants issued in PIPE, net of offering cost (in shares) 2,549,573        
Issuance of warrants to consultants   8,826,154     8,826,154
Common stock issued on ATM, net of offering costs $ 11 30,738     30,749
Common stock issued on ATM, net of offering costs (in shares) 10,759        
Deemed dividend - warrant repricing   32,827 (32,827)    
Net loss     (18,593,563) (12,619) (18,606,182)
Ending Balance at Dec. 31, 2025 $ 4,774 416,617,812 (397,786,765) (375,673) 18,460,148
Ending Balance (in shares) at Dec. 31, 2025 4,772,271        
Beginning Balance at Sep. 30, 2025 $ 1,663 381,463,459 (379,160,375) (363,054) $ 1,941,693
Beginning Balance (in shares) at Sep. 30, 2025 1,662,601       1,662,601
Increase (Decrease) in Stockholders' Equity          
Net loss         $ (25,271,341)
Ending Balance at Mar. 31, 2026 $ 5,669 416,951,861 (404,451,992) (375,605) 12,129,933
Ending Balance (in shares) at Mar. 31, 2026 5,667,469        
Beginning Balance at Dec. 31, 2025 $ 4,774 416,617,812 (397,786,765) (375,673) 18,460,148
Beginning Balance (in shares) at Dec. 31, 2025 4,772,271        
Increase (Decrease) in Stockholders' Equity          
Exercise of warrants, cashlessly $ 695 (695)      
Exercise of warrants, cashlessly (in shares) 695,270        
Stock based compensation expense   334,944     334,944
Shares issued upon restricted stock vesting $ 200 (200)      
Shares issued upon restricted stock vesting (in shares) 199,928        
Net loss     (6,665,227) 68 (6,665,159)
Ending Balance at Mar. 31, 2026 $ 5,669 $ 416,951,861 $ (404,451,992) $ (375,605) $ 12,129,933
Ending Balance (in shares) at Mar. 31, 2026 5,667,469